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A mutation in the serine protease TMPRSS4 in a
novel pediatric neurodegenerative disorder
Piya Lahiry1,2, Lemuel Racacho3, Jian Wang1, John F Robinson1, Gregory B Gloor4, C Anthony Rupar4,5,
Victoria M Siu5, Dennis E Bulman3 and Robert A Hegele1,4,6*

Abstract
Background: To elucidate the genetic basis of a novel neurodegenerative disorder in an Old Order Amish pedigree
by combining homozygosity mapping with exome sequencing.
Methods and results: We identified four individuals with an autosomal recessive condition affecting the central
nervous system (CNS). Neuroimaging studies identified progressive global CNS tissue loss presenting early in life,
associated with microcephaly, seizures, and psychomotor retardation; based on this, we named the condition
Autosomal Recessive Cerebral Atrophy (ARCA). Using two unbiased genetic approaches, homozygosity mapping
and exome sequencing, we narrowed the candidate region to chromosome 11q and identified the c.995C > T
(p.Thr332Met) mutation in the TMPRSS4 gene. Sanger sequencing of additional relatives confirmed that the
c.995C > T genotype segregates with the ARCA phenotype. Residue Thr332 is conserved across species and
among various ethnic groups. The mutation is predicted to be deleterious, most likely due to a protein structure
alteration as demonstrated with protein modelling.
Conclusions: This novel disease is the first to demonstrate a neurological role for a transmembrane serine
proteases family member. This study demonstrates a proof-of-concept whereby combining exome sequencing
with homozygosity mapping can find the genetic cause of a rare disease and acquire better understanding of a
poorly described protein in human development.
Keywords: Autosomal recessive cerebral atrophy (ARCA) syndrome, Neurodegeneration, Trypsin-like serine
protease, Homozygosity, Microarray, Exome sequencing, Autosomal recessive inheritance, Old Order Amish

Background
Neurodegenerative disorders can be defined as disorders
with progressive deterioration of neurological functions
such as loss of vision, hearing, and motor function along
with previously attained skills [1]. Such degeneration is
frequently associated with seizures, feeding issues and
intellectual impairment. Neurodegenerative disorders can
be etiologically classified under acquired and inherited
causes [1]. Acquired causes are most common, and
include chronic viral infections, toxin deposition such as
heavy metal ingestion and cancer chemotherapy, and drug
metabolites [2]. Inherited causes can be due to specific
genetic and metabolic defects, such as Rett syndrome,
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mitochondrial disorders such as MELAS, toxin-generating
defects such as PKU, Wilson disease and HallervordenSpatz syndrome, lysosomal storage diseases such as
Niemann-Pick (types A and C) and Gaucher disease, and
leukodystrophies such as Alexander disease [2].
Neurodegeneration in these disorders can involve both
the grey and white matter of the brain and spinal cord.
Injury of grey matter is irreversible and manifests as seizures, psychomotor retardation, visual impairment and
extrapyramidal disturbances such as akathisia (inability
to remain motionless) [2]. On the other hand whitematter, mainly represented by myelinated axons, involves
disease that is dominated by motor difficulties and
chronic encephalopathy [2].
Herein we describe a novel neurodegenerative disorder
affecting four infants in a highly consanguineous Amish
pedigree. Using homozygosity mapping and exome
sequencing, we identified a mutation in TMPRSS4, a

© 2013 Lahiry et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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transmembrane serine protease, whose physiological role
is poorly understood. This work exemplifies the use of
unbiased approaches to find novel proteins implicated in
rare single-gene disorders.

Materials and methods
This study had ethics approval by the Office of Research
Ethics at the University of Western Ontario (number
07920E). Four participating families from an Old Order
Amish community in Ontario provided informed consent and received no financial compensation. All four
probands had thorough clinical evaluations, including
MRI-head scans. In addition, an autopsy of one proband
(V-9) was completed. The pedigrees of the families were
assembled through interviews and local Amish community records. In addition, DNA from umbilical cord
blood and buccal swabs were extracted from 208 ARCAunaffected individuals from the Old Order Amish community to determine mutant allele frequency.
Genomic DNA of peripheral blood from 3 affected
(V-10, V-12, V-14) and 5 unaffected (V-6, V-8, IV-8,
V-15, IV-12) parents and siblings were genotyped
using Genome-Wide Human SNP Array 6.0 at London
Regional Genomics Centre (http://www.lrgc.ca). Genotypes were called using Affymetrix Genotyping Console,
with quality control thresholds for subject call rate
(>90%), SNP call rate (95%), Hardy-Weinberg equilibrium (P > 0.0001) and minor allele frequency (>1%).
Due to the consanguineous nature of the pedigree,
family-based autozygosity or homozygosity mapping
was performed using Agilent GT v2.0 software to scan
the genotyped SNPs for runs of homozygous blocks.
The location scores for each of these homozygous
blocks were calculated within Agilent GT v2.0. While a
few homozygous block were seen, the one on chromosome 11q clearly had the highest location score and this
block was considered to most likely harbour the disease
gene [3].
For exome sequencing, targeted enrichment and sequencing were performed on DNA extracted from the
peripheral blood of individuals V-10 and V-12, both
with typical features of ARCA. Exome enrichment was
performed with Agilent SureSelect Human All Exon
50 MB Kit at The Centre for Applied Genomics (http://
www.tcag.ca). Paired-end sequencing was performed on
Illumina GAII generating 100-bp reads, which were
subsequently aligned to the human reference genome
sequence (hg19/ GRCh37), using NextGENe software
and CLC-Bio Workbench.
TMPRSS4 in the linked region on chromosome 11q
was first screened by Sanger sequencing in an affected
individual, a parent, an unaffected sibling, and a nonAmish control. Co-segregation of the TMPRSS4 variation
with disease was demonstrated with direct sequence
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analysis in a total of 18 family members, including the
affected individuals. TaqMan assays were used for identifying allele frequency of the TMPRSS4 variation in
exon 10, c.995C > T (GI:145701031), within 208 Old
Order Amish controls and 2382 ethnically diverse and
healthy non-Amish controls. TaqMan quantitative realtime PCR assays provided allele discrimination using
two allele-specific TaqMan probes synthesized for
detecting the TMPRSS4 variation (allele C: 5′ VIC-CTG
CTT CGT AAA GCC and mutant allele A: 5′ FAMCTG CTT CAT AAA GCC).
Conservation of the TMPRSS4 protein across species
was determined with ClustalW, a multiple-sequencealignment computer program [4]. Impact of the amino
acid mutation on TMPRSS4 protein structure, function,
and pathological implication was predicted with four
online tools, namely PolyPhen-2, Panther, SNPs3D, and
PMUT.

Results
Clinical characterization of autosomal recessive cerebral
atrophy (ARCA)

Four affected children were identified in an Old Order
Amish pedigree (Figure 1) to have similar clinical features and subsequently a thorough clinical evaluation
was performed on them (Table 1).
V-9, born in 2004, was the product of an uncomplicated pregnancy and delivery at 36.5 weeks gestation,
with a head circumference of 30 cm (<3rd percentile).
Her neonatal period was unremarkable until 6 weeks of
age, when the infant refused to suck. By 3 months of
age, she had frequent reflux, was agitated during feeds
and was generally irritable. By 7 months of age, she had
regressed such that she was unable to smile or laugh, to
rollover or sit-up unsupported, and could neither ‘babble’
nor ‘coo’. Growth charts demonstrated progressive microcephaly with head circumference at <3rd percentile at 6.5
months of age. Musculoskeletal examinations demonstrated spasticity (fisted hands and leg scissoring), abnormal tone and constant akathisia with no notable seizure
activity. Visual impairment was suggested since she was
unable to follow objects by 1 year of age. Investigations
ruled out known inborn errors of metabolism and mitochondrial disorders. Of note she had abnormal blood
work of unknown significance demonstrating elevated ammonia, manganese, lactate, and platelets levels. MRI and
CT scans revealed severe diffuse loss of cerebral volume
with symmetrical enlargement of ventricular space, affected grey and white matter with a thinned corpus
callosum, however, the cerebellum, brainstem and midbrain were spared. Eventually, she was placed in palliative
care since she was unable to swallow or drink independently. She died at 18 months most likely due to failure to
thrive, with no follow-up autopsy.
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Figure 1 Old Order Amish pedigree with consanguinity (indicated by the double lines) has four individuals with ARCA, a disease with
an autosomal-recessive mode of inheritance. Affected individuals are shown as blackened squares (male) and circles (female). Diagonal lines
across symbols indicate deceased individuals.

V-10 was born in 2000 at gestational age of 38 weeks
following a normal pregnancy and delivery. Once again,
the infant was developing appropriately until 3 months of
age when she stopped gaining weight, stopped smiling,
was unable to ‘coo’ nor roll over. Suckling regressed by
5 months of age and she had a G-tube insertion by one
year of age. Her family doctor noted microcephaly with no
head growth post 6 weeks of birth and premature anterior
fontanelle closure. At 2 years of age, her head circumference was recorded at 35.5 cm (<3rd percentile). By
6 months of age she developed seizures described to cause
head deviation, ipsilateral arm extension, lip biting and a
high-pitched scream followed by a brief period of sleep
and then arousal. Interestingly, EEG performed at
9 months demonstrated no epileptiform activity. These
seizure-like episodes increased in frequency by 15 months
of age such that she was placed on a palliative seizure
therapy regimen. She also had arm stiffness and leg
scissoring indicating spasticity, akathisia, brisk reflexes
and hypotonic lower extremities. In addition, she was irritable and startled easily. Investigations ruled out MELAS,
inborn errors of metabolism and Hallervorden-Spatz syndrome, and muscle biopsies were normal. MRI demonstrated enlarged lateral and 3rd ventricles with marked
atrophy of cortical tissue, sparing the pons and cerebellum
(Figure 2A). The infant died at 2 years of age. Although
autopsy was unable to prove cause of death, it was concluded that the seizures were not severe enough to cause
cortical degeneration. Gross evaluation of brain revealed a
pale thalami, normal occipital region, brainstem, and
cerebellum as well as symmetrical atrophy of cerebral hemispheres. Microscopic evaluation of the brain demonstrated

unaffected brain stem and meninges, material deposition in neurons, like calcium, as well as severe loss of
myelin in white matter. The rest of the organs were unremarkable on autopsy.
V-12 was born at 39 weeks gestation in 2001 following
an uncomplicated pregnancy and delivery. He had a relatively unremarkable neonatal period except that his
parents noted him to have constant akathisia only while
awake. He was microcephalic since 3 months of age and
was recorded to have a premature anterior fontanelle closure with a head circumference measurement of 43.3 cm
at 4 years of age (<3rd percentile). Regression of developmental milestones began within 1 month of age when he
stopped smiling, had exaggerated startle response by
3 months; at 4.5 years he was able to kick some toys and
bat at objects, but could neither speak nor gesture. He
had a diagnosis of cortical visual impairment with atrophic
optic fundi and nystagmus by 2 years of age. By 3 months
of age, he began having episodes of repetitive extension of
arms and hands associated with stiffening of the body with
a shriek-like cry with EEG findings of generalized epileptiform activity. By 4 years of age, he was prescribed monthly
botox injections and daily oral baclofen, and was wheelchair bound due to the spasms and abnormal increased
muscle tone, which began by 11 months of age. He also
had a G-tube insertion to prevent his recurrent aspiration
pneumonitis episodes. Investigations ruled out known
inborn errors of metabolism and MELAS. Blood work
demonstrated elevated manganese, lactate, and platelet
levels. Imaging consistently showed cerebral atrophy and
ventriculomegaly with subtle atrophy of brainstem and
corpus callosum. At 12 years of age, he continues to live
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Table 1 Clinical description of the four ARCA-affected individuals
Affected individuals (year of birth)
V-9 (2004)

V-10 (2000)

V-12 (2001)

V-14 (1999)

Karyotype

46, XX

46, XX

46, XY

46, XY

Pregnancy
and delivery

Uncomplicated

Uncomplicated

Uncomplicated

Clomidinduced but
uncomplicated

GA at
delivery

36.5 weeks

38 weeks

39 weeks

39 weeks

Weight at
birth

2455 g (10th percentile)

2610 g (10th percentile)

N/A

2550 g (<3rd
percentile)

Length at
birth

47.5 cm (25th percentile)

N/A

N/A

N/A

HC, at birth*

30 cm (<3rd percentile)

N/A

N/A

N/A

Fontanelle
closure

at 6.5 mo: Anterior open (N),
posterior closed (N)

at 2 mo: Anterior closed (abN)

at 5.5 mo: Anterior closed
(abN)

at 8 mo:
Anterior
fontanelle
closed

Status

died at 18 months

died at 2 years

alive at 12 yrs

alive at 14 yrs

Autopsy

-

+

-

-

Suckling

stopped by 6 weeks

stopped by 5 mo

N/A

N/A

Smile

started at 2 mo, stopped by
7 mo

Started at 2 mo, stopped by 3 mo

no reflexive smile at 1 mo

Started at 2
mo, stopped
by 4 mo

Sitting

unable at 7 mo

unable at 8 mo

unable at 4 yrs

unable at 5 yrs

Babbling

unable at 7 mo

unable at 8 mo

no speech at 4 yr

N/A

Seizures/
Epilepsy

-

+

+

+

EEG

N/A

marked abnormality with low
cortical activity, no epileptiform
activity noted

generalized central
epileptiform activity

Grade 1
generalized
and
suppressed
cerebral
activity

Spasticity

+ (fisted hands, legs scissoring)

+ (legs scissoring, arms stiff)

+ (myoclonic spasm due
+ (clonus of R
to sound/light touch, fisted ankle)
hands)

Reflexes

N/A

brisk, clonus of L ankle

unable to assess

hyperreflexia

Tone

hypotonic trunk, hypertonic
extremities

Hypotonic lower extremities

hypotonic trunk,
hypertonic extremities

hypertonic
extremities

Irritable

++

++

+++

+++

Head
circumference,
last recorded

36.5 cm @ 6.5 mo (<3rd
percentile)

35.5 cm @ 2 yrs (<3rd percentile)

43.3 cm @ 4 yrs (<3rd
percentile)

39 cm at 8.5
mo (<3rd
percentile)

Development
milestones

Neurological
signs

Vision and
Hearing

Akathisia

+

+

++ (while awake)

++

Startles

easily

easily

easily however less
pronounced presently

easily however
less
pronounced
presently

Visual
impairment

inconsistent with cues

infrequent, strabismus

cortical, horizontal +
vertical nystagmus

cortical visual
impairment,
eyes roll back

Fundoscopy

N/A

N/A

mild atrophic fundi

hypoplastic
optic nerve
and fovea
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Table 1 Clinical description of the four ARCA-affected individuals (Continued)
Other organs

Hearing

Normal

normal

normal

normal

G-tube

-

at 1 yr

at 4 yrs due to recurrent
aspiration pneumonitis

-

Elevated Mn, lactate, and
platelets

Elevated CK,
CK-MB, and
platelets

Abnormal
Bloodwork
MRI

CT

Elevated ammonia, Mn, lactate,
platelets
Age at time of
imaging

10 mo

8 mo, 11 mo,

3 mo, 12 mo

7 mo, 13 mo,
6 yrs 7 mo

Description

Severe symmetrical cerebral
volume loss, gray and white
matter affected, thinned corpus
callosum. Cerebellum,
brainstem, midbrain and
supratentorial deep grey matter
are unaffected.

Enlarged lateral and 3rd ventricles,
severe uniform atrophy of the
brain with subcortical white matter
loss. Normal spine to T2,
cerebellum and pons.

Marked progressive
cerebral and cerebellar
atrophy with basal ganglia
involvement

Prominent
ventricles, thin
white and
grey matter

Age at time of
imaging

6 mo

3 mo

Description

Prominent subarachnoid spaces
and ventricular system.
Infratentorial compartment is
normal, including cerebellum
and 4th ventricle

Generalized cerebral
atrophy with associated
ventriculomegaly, difficult
to differentiate between
grey/white matter

* Based on: Barbier et al, 2013. Pediatrics. “New Reference curves for Head Circumference at Birth, by GA”. Abbreviations: N/A, not available; "-", not determined.

with his family and is fully dependent on others, however
his seizures are better controlled seizures and he is less
irritable.
V-14 was the first known proband with ARCA in this
pedigree born in 1999. He was a product of a clomidinduced twin pregnancy with a fraternal sister who
continues to have normal development. Delivery was induced at 39 weeks with a birth weight of 2550 grams (<3rd
percentile). His neonatal period was unremarkable overall.
He was microcephalic prior to development regressions,
which were first noted after 4 months of age. By 4 months
he stopped smiling, laughing, cooing, and had abnormal
tone. By 9 months of age, he would be easily startled, irritable, and agitated while feeding. By 5 years, he could only
hold his head up, was severely spastic, had hyperreflexive
extremities, and was unable to eat solid foods. By 3 years
of age he was diagnosed with visual impairment due to
cortical abnormalities, with hypoplastic optic nerve and
fovea. Investigations demonstrated no lysosomal, peroxisomal or metabolic disorders. EEG demonstrated
supressed Grade 1 cerebral activity with generalized
abnormal cortical activity. MRI of spine demonstrated
no abnormalities; however, ventricles and sulci were
prominent in size and severely atrophic white and gray
matter (Figure 2B). He is presently 14 years old and
continues with generalized spasticity and requires a
pureed diet, which he regularly chokes on. He is less
irritable and on no medications.
Overall, all four children were products of an unremarkable pregnancy, delivery and neonatal period. However, acquired microcephaly was noted within 2 months

of birth. By 4 months of age, the infants displayed constant irritability, regression of developmental milestones,
akathisia, increased startle response, spasticity, abnormal
tone, visual impairment and seizures. In two of the four
children, the anterior fontanelle had prematurely closed.
Brain imaging of all four affected children revealed a characteristic ventriculomegaly and progressive symmetrical
atrophy of brain matter—in particular the white and grey
matter of the cortex, sparing the infratentorial segments,
such as the midbrain, brainstem and cerebellum.
Based on the clinical findings and imaging, we named
this novel disorder as Autosomal Recessive Cerebral
Atrophy (ARCA).
Molecular investigations

Exome sequencing was performed on 2 affected individuals (V-10 and V-12) and a filtering method was applied to identify unique nucleotide variants, which
yielded 42 and 77 novel homozygous sequence variants
in individuals V-10 and V-12, respectively (Figure 3A).
Homozygosity mapping revealed a candidate region, the
homozygous block with the highest location score
(Figure 3B), encompassing 4.5 Mbp in chromosome 11q
with a location score of 303 comprising of 872 SNPs
and 91 genes (Figure 3B). Within this candidate region in chromosome 11, only 1 of the unique nucleotide
variants was present in homozygous state in both affected
individuals while their parents were obligate heterozygotes. The variant is a C to T at c.995 in exon 10 of the
TMPRSS4 gene, resulting in an amino acid change from
threonine (T) to methionine (M) at residue 332 (T332M,
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Figure 2 Coronal and sagittal views of T1-weighted MRI-head of ARCA patients demonstrating diffuse cortical atrophy and
ventriculomegaly. A) V-10 at 8 months of age, B) V-14 at 10 months of age.

Figure 4). Sanger sequencing of TMPRSS4 c.995C > T in
the pedigree is consistent with an autosomal recessive
inheritance pattern, and segregates with the ARCA
phenotype (see Additional file 1). The frequency of the
T allele was assessed within 208 Old Order Amish community members (excluding the pedigree). None had
the TT genotype while 12% had the CT genotype (carrier rate); thus 1 in 250 Old Order Amish are predicted
to have the TT genotype. In 2382 geographically and
ethnically diverse controls, all had the CC genotype
suggesting that the TT genotype is a private mutation
within this Old Order Amish community.
In silico investigations

To better understand the biological significance of this
mutation, various bioinformatics strategies were employed.
Residue 332 is within the trypsin-like serine protease
domain (Figure 5A). The ClustalW protein sequence alignment program showed strong conservation of this residue
among TMPRSS4 orthologs from other organisms
(Figure 5B). PolyPhen, Panther and SNPs3D, similarly
showed that the T to M change at residue 332 would be
deleterious or damaging to TMPRSS4 function.

The crystal structure of TMPRSS4 has yet to be
published and there is no related structure with an
identity >40%. However, examination of the domain
structure of TMPRSS4 shows that the C-terminal half of
the protein is an excellent match (E-value of 3.1e-91) to
the trypsin-like serine protease family (cd00190) [5].
Alignment of the TMPRSS4 sequence with the available
structures of this family, using the Cn3D tool [6], demonstrate that residue 332 is in a conserved loop that
borders the active site. In majority of these homologous
structures, the residue side chain is partially exposed on
the surface and in one structure (1MKX) the side chain
is directed into the active site. In either case, the T332M
change—a polar to a non-polar amino acid coupled with
a longer side chain—would likely result in a steric clash
that could lead to substrate binding alteration and thus
altered TMPRSS4 function.

Discussion and conclusion
We describe a novel pediatric disorder in an Old
Order Amish community, named Autosomal Recessive
Cerebral Atrophy (ARCA) due to a progressive brain
atrophy leading to neurodegenerative symptoms
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Figure 3 Genetic investigations to find the causative mutation for ARCA. A) Variant filtration of exome sequencing data of two affected
individuals, V-10 and V-12. Non-synonymous is defined as a change that alters the amino acid. B) Homozygosity mapping narrows candidate
region to 11q23.3, containing 91 genes.

including loss of developmental milestones, seizures
and loss of motor function.
Although there was slight variability in the age of
developmental milestone regression, by 4 months of age
all 4 infants displayed irritability, akathisia, increased
startle response, abnormal reflex and tone, visual impairment, as well as seizures or seizure-like episodes. In
addition, the infants were noted to have microcephaly
early in life and brain imaging revealed a characteristic
ventriculomegaly and progressive symmetrical atrophy of
brain matter, particularly cortical white and grey matter.
Even though the degenerative process of the brain matter
most likely started earlier in development, the infants may
have been asymptomatic perinatally or during the neonatal stage, since the cerebrum is functionally silent during the early weeks of life [7]. It is likely that 2 of the 4
children continue to survive due to the level of medical

intervention provided by the caregivers rather than biological variability in the severity of the disease.
After conducting a comprehensive literature search of
the clinical descriptions of ARCA, we identified three
similar yet distinct syndromes. For instance, patients
with micropthalmia, brain atrophy (MOBA; MIM:
611222), develop extensive atrophy of white and grey
matter after 6 months of life leading to progressive spasticity and seizures. However, unlike ARCA, MOBA patients also have congenital ocular malformations [8]. A
case report, in 2011, describes two Japanese sisters with
failure of postnatal brain growth with similar brain MRI
findings to those of ARCA-affected patients. However,
these sisters also had dysmorphic facial features
and simplified gyri that were not present in ARCA
[9]. Furthermore, West syndrome or Early Infantile
Epileptic Encephalopathy 5 (EIEE5, MIM: 613477) is
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Figure 4 The genomic structure of TMPRSS4 gene consists of 13 coding exons with a nucleotide change in exon 10 (indicated in red)
that alters threonine to methionine at residue 332 (T332M). DNA sequence tracings of TMPRSS4 exon 10 in an ARCA affected (top), T332M
heterozygote (middle), and an unaffected (bottom) individual. For each tracing, the nucleotide sequence is shown at the top followed by the
single-letter amino acid code and codon numbers beneath.

similar to ARCA in that the seizures manifest around
3 months of age due to brain atrophy [10]. However
this atrophy is mostly localized to the brainstem due
to hypomyelination of white matter in this region.
EIEE5 is due to a heterozygous mutation in SPTAN1
gene encoding spectrin, a cytoskeletal protein involved
in scaffolding [11].

Using exome sequencing and homozygosity mapping
we identified a homozygous missense (T332M) mutation in the serine protease, TMPRSS4. This mutation
segregated with the disease and no carriers were found
outside of the Amish community, giving genotypic and
statistical evidence that the TMPRSS4 mutation is likely
causative of ARCA. Bioinformatics further illustrated that

Figure 5 TMPRSS4 protein structure and amino acid sequence alignment with its orthologs. A) A schematic representation of TMPRSS4
protein domain structure. At the N-terminal the protein has a transmembrane domain, a LDL-receptor A domain, and a scavenger receptor
domain. The C-terminal encodes for the trypsin-like serine protease domain which contains the catalytic triad amino acids (histidine, aspartic acid,
serine). The T332 residue (indicated with a red star) is also found within this domain. B) Multiple alignments (using ClustalW) demonstrate that
T332 residue (highlighted in red) is highly conserved across a representative set of species-specific TMPRSS4 orthologs.
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this T to M mutation at residue 332, most likely affects
protein function due to: 1) high evolutionary conservation
of the residue, 2) program predictions that demonstrate
pathological consequence, and 3) predicted changes in
protein structure leading to instability.
Serine proteases, such as trypsin-like proteases are
ubiquitously distributed and play pivotal roles in the
gastrointestinal, reproductive, and immune systems
[12]. Trypsin-like serine-proteases have been implicated
in brain plasticity, neural development, neurodegeneration and neuroregeneration through human disorders and knock-out zebra fish models [13]. Specifically,
one of the first serine proteases shown to be involved in
human non-syndromic mental retardation was neurotrypsin [14]. Of note, the family members of Type II
transmembrane serine proteases (TMPRSSs), TMPRSS2,
TMPRSS1, TMPRSS3, and TMPRSS5 have only been
implicated in certain types of sensorineural deafness [15].
TMPRSS4 is expressed in the gastrointestinal tract,
skeletal muscle and brain. It is highly expressed on the cell
surface of pancreatic, thyroid, lung, and other cancer
tissues, with potential biological implication in cell invasion and migration [16].
This study demonstrates that TMPRSS4 is strongly
implicated in the causation of this autosomal recessively
inherited pediatric neurological disease. This information can now be used for genetic counselling in the community and to stimulate mechanistic research on this
protein and mutation.

Additional file
Additional file 1: Figure of the pedigree illustrating ARCA
phenotype along with genotype data Figure legend (description)—
Sanger sequencing of TMPRSS4 c.995C>T in the pedigree is
consistent with an autosomal recessive inheritance pattern and
segregates with the ARCA phenotype. The top half of each symbol
indicates whether the individual is ARCA affected (black) or unaffected
(white). The bottom half of the symbol represents the genotype with T
shown in black and C shown in white.
Abbreviations
ARCA: Autosomal recessive cerebral atrophy; TMPRSS4: Transmembrane
protease, serine 4; SNP: Single nucleotide polymorphism; Gtube: Gastrostomy tube; MELAS: Mitochondrial encephalomyopathy, lactic
acidosis, and stroke-like episodes; EEG: Electroencephalogram.
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